When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a …
Continue reading “Here’s why PAR is worth watching now more than ever?”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Tesla’s recent share price surge may only be the start, according to ARK Investment Management. A recent price target set by ARK shows some very opportunistic views on Tesla’s future …
Continue reading “Tesla predicted to hit $7000 by 2024 says ARK Investment Management”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Amazon is currently priced at $1,861.64 (AMZN), a 120,000% price increase since it’s IPO in 1997. Amazon’s come up is nothing short of remarkable, with the distribution giant reaching $1 …
Continue reading “An $800 investment in Amazon at IPO would now be worth over $1,000,000”
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Introduction Cann Group (CAN) Cann Group (CAN) is an Australian medicinal cannabis company. Cann aims to research, cultivate, and manufacture a range for medicinal cannabis products for patients in Australia …
